- Home
- ESGL vs TARA Comparison
ESGL vs TARA Comparison
Compare ESGL & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- TARA
- Stock Information
- Founded
- ESGL 1999
- TARA N/A
- Country
- ESGL Singapore
- TARA United States
- Employees
- ESGL N/A
- TARA N/A
- Industry
- ESGL
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESGL
- TARA Health Care
- Exchange
- ESGL Nasdaq
- TARA Nasdaq
- Market Cap
- ESGL 165.3M
- TARA 165.5M
- IPO Year
- ESGL N/A
- TARA N/A
- Fundamental
- Price
- ESGL $3.75
- TARA $5.53
- Analyst Decision
- ESGL
- TARA Strong Buy
- Analyst Count
- ESGL 0
- TARA 6
- Target Price
- ESGL N/A
- TARA $19.80
- AVG Volume (30 Days)
- ESGL 5.8K
- TARA 365.8K
- Earning Date
- ESGL 12-26-2025
- TARA 11-10-2025
- Dividend Yield
- ESGL N/A
- TARA N/A
- EPS Growth
- ESGL N/A
- TARA N/A
- EPS
- ESGL N/A
- TARA N/A
- Revenue
- ESGL $5,328,277.00
- TARA N/A
- Revenue This Year
- ESGL N/A
- TARA N/A
- Revenue Next Year
- ESGL N/A
- TARA N/A
- P/E Ratio
- ESGL N/A
- TARA N/A
- Revenue Growth
- ESGL N/A
- TARA N/A
- 52 Week Low
- ESGL $0.90
- TARA $2.21
- 52 Week High
- ESGL $4.32
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- ESGL 44.10
- TARA 62.79
- Support Level
- ESGL $3.44
- TARA $4.11
- Resistance Level
- ESGL $3.95
- TARA $5.42
- Average True Range (ATR)
- ESGL 0.13
- TARA 0.35
- MACD
- ESGL -0.03
- TARA 0.02
- Stochastic Oscillator
- ESGL 57.41
- TARA 96.23
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).